Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action.

Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, Spear KL, Large TH, Campbell UC, Hanania T, Leahy E, Koblan KS.

J Pharmacol Exp Ther. 2019 Oct;371(1):1-14. doi: 10.1124/jpet.119.260281. Epub 2019 Aug 1.

PMID:
31371483
2.

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Newman-Tancredi A, Kleven MS.

Psychopharmacology (Berl). 2011 Aug;216(4):451-73. doi: 10.1007/s00213-011-2247-y. Epub 2011 Mar 11. Review.

PMID:
21394633
3.

Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.

Tuplin EW, Holahan MR.

Curr Neuropharmacol. 2017 Nov 14;15(8):1192-1207. doi: 10.2174/1570159X15666170413115754.

5.

The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.

Newman-Tancredi A.

Curr Opin Investig Drugs. 2010 Jul;11(7):802-12. Review.

PMID:
20571976
6.

The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist.

Natesan S, Reckless GE, Barlow KB, Odontiadis J, Nobrega JN, Baker GB, George SR, Mamo D, Kapur S.

Psychopharmacology (Berl). 2008 Aug;199(2):275-89. doi: 10.1007/s00213-008-1172-1. Epub 2008 Jun 3.

PMID:
18521575
7.

Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats.

Tarland E, Franke RT, Fink H, Pertz HH, Brosda J.

Psychopharmacology (Berl). 2018 Jan;235(1):99-108. doi: 10.1007/s00213-017-4747-x. Epub 2017 Oct 3.

8.

Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.

Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY.

Behav Brain Res. 2015 May 15;285:165-75. doi: 10.1016/j.bbr.2014.09.040. Epub 2014 Oct 16.

PMID:
25448429
9.

In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Assié MB, Dominguez H, Consul-Denjean N, Newman-Tancredi A.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):441-50. Epub 2006 Sep 1.

PMID:
16947046
10.

Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.

Auclair AL, Kleven MS, Besnard J, Depoortère R, Newman-Tancredi A.

Neuropsychopharmacology. 2006 Sep;31(9):1900-9. Epub 2006 Jan 18.

11.

Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.

Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, Kikuchi T.

J Pharmacol Exp Ther. 2014 Sep;350(3):605-14. doi: 10.1124/jpet.114.213819. Epub 2014 Jun 19. Erratum in: J Pharmacol Exp Ther. 2014 Dec;351(3):686-7.

PMID:
24947464
12.

Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.

Takahashi S, Sonehara K, Takagi K, Miwa T, Horikomi K, Mita N, Nagase H, Iizuka K, Sakai K.

Psychopharmacology (Berl). 1999 Aug;145(3):295-302.

PMID:
10494578
13.

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A.

Br J Pharmacol. 2007 May;151(2):266-77. Epub 2007 Mar 20.

14.

Quetiapine : A Review of its Use in Schizophrenia.

Gunasekara NS, Spencer CM.

CNS Drugs. 1998 Apr;9(4):325-40. doi: 10.2165/00023210-199809040-00007.

PMID:
27521016
15.
16.
17.

Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.

Ballmaier M, Zoli M, Mazzoncini R, Gennarelli M, Spano F.

Psychopharmacology (Berl). 2001 Dec;159(1):105-10. Epub 2001 Sep 11.

PMID:
11797077
18.

The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.

Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KCF.

Eur Neuropsychopharmacol. 2016 Feb;26(2):208-224. doi: 10.1016/j.euroneuro.2015.12.020. Epub 2015 Dec 11.

PMID:
26723167
19.

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-Tancredi A.

Br J Pharmacol. 2007 May;151(2):253-65. Epub 2007 Mar 20.

20.

The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.

Fejgin K, Safonov S, Pålsson E, Wass C, Engel JA, Svensson L, Klamer D.

Psychopharmacology (Berl). 2007 Apr;191(2):377-85. Epub 2007 Jan 19.

PMID:
17235612

Supplemental Content

Support Center